A new comprehensive health platform company will focus on elevating value-based care capabilities with providers, payers, healthcare systems, and ACOs.
Rajesh Shrestha,
Intermountain Healthcare is forming a new value-based care company.
Called Castell, the company will offer a comprehensive platform of tools and services to support practice transformation and improvement. These resources will help all parts of the health ecosystem promote wellness for patients and excel within a value-based healthcare world.
“Intermountain has actively developed tools and initiatives to help providers and others successfully implement value-based care for years,” says Rajesh Shrestha, president and CEO of Castell. “Castell is one part of that work that we’re excited to officially share now."
Related article: Intermountain Healthcare, deCODE Launch Largest DNA Mapping Project in United States
The new company will offer a comprehensive platform of tools and services to support transformation and improvement:
“We continually see that without the right level of support, it is difficult for providers, health systems, payers, and others to thrive in a value-based healthcare world,” Shrestha says. “Intermountain’s day-to-day frontline experience and success in value-based care management programs make us uniquely prepared to extend our services to others through Castell. We are energized by this opportunity to simplify value-based care and help set the direction for the healthcare of the future.”
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More